Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

NCT04662112 is registered in ClinicalTrials.gov with Asan Medical Center as lead sponsor.

NCT NCT04662112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04662112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Phase I/IIa Study of NASOX (Nal-IRI + S-1 + Oxaliplatin) as First-line Treatment for Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma
Lead sponsor
Asan Medical Center
Phase
Phase 1/2
Overall status
Completed
Start date
June 15, 2021
Completion date
December 30, 2024
Enrollment
40 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer, pancreatic ductal adenocarcinoma